SEC Comment Letter for Keros Therapeutics, Inc. (KROS) (CIK 0001664710) (KROS) — Nov 9, 2020
Keros Therapeutics, Inc. (KROS) (CIK 0001664710)
Date: Nov. 9, 2020 · CIK: 0001664710 · Accession: 0000000000-20-010737
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo November 9, 2020 Esther Cho Head of Legal Keros Therapeutics, Inc. 99 Hayden Avenue, Suite 120, Building E Lexington, Massachusetts 02421 Re:Keros Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted November 3, 2020 CIK No. 0001664710 Dear Ms. Cho: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Laura Crotty at 202-551-7614 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Sansom
Show Raw Text
United States securities and exchange commission logo
November 9, 2020
Esther Cho
Head of Legal
Keros Therapeutics, Inc.
99 Hayden Avenue, Suite 120, Building E
Lexington, Massachusetts 02421
Re:Keros Therapeutics, Inc.
Draft Registration Statement on Form S-1
Submitted November 3, 2020
CIK No. 0001664710
Dear Ms. Cho:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Laura Crotty at 202-551-7614 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ryan Sansom